论文部分内容阅读
目的探讨血清HE4与CA125联合检测对卵巢癌的早期诊断、筛查鉴别中的作用。方法采用酶联免疫吸附法(ELISA)和化学发光免疫分析法对45例卵巢癌患者、45例盆腔良性疾病患者和45例正常人群进行血清HE4、CA125检测,分析两者单独及联合检测在早期诊断卵巢癌中的价值。结果卵巢癌组血清HE4和CA125水平均显著高于良性组和对照组(P<0.05),卵巢癌组HE4和CA125阳性率明显高于盆腔良性疾病组,而在正常对照组中这两种标志物表达均为阴性。单独检测卵巢癌血清HE4、CA125,特异性为71.1%和73.3%,敏感性为93.3%和86.7%;两者联合检测的特异性和敏感性分别为93.3%和97.8%。此外,Ⅲ~Ⅳ期卵巢癌患者血清CA125水平和HE4、CA125检测阳性率明显高于Ⅰ~Ⅱ期卵巢癌患者(P<0.05)。结论 HE4与CA125联合检测是目前比较理想的检测方法,为早期诊断和治疗卵巢癌提供了依据。
Objective To investigate the role of combined detection of serum HE4 and CA125 in early diagnosis and screening of ovarian cancer. Methods Serum levels of HE4 and CA125 were detected in 45 patients with ovarian cancer, 45 patients with pelvic benign disease and 45 normal controls by enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay. Diagnosis of ovarian cancer in the value. Results The levels of serum HE4 and CA125 in ovarian cancer group were significantly higher than those in benign group and control group (P <0.05). The positive rates of HE4 and CA125 in ovarian cancer group were significantly higher than those in benign pelvic disease group, while those in normal control group The expression was negative. The detection of ovarian cancer serum HE4 and CA125 alone was 71.1% and 73.3%, and the sensitivity and specificity were 93.3% and 86.7% respectively. The specificity and sensitivity of the combined detection of the two drugs were 93.3% and 97.8% respectively. In addition, the serum CA125 levels and the positive rates of HE4 and CA125 in stage Ⅲ ~ Ⅳ ovarian cancer patients were significantly higher than those in stage Ⅰ ~ Ⅱ ovarian cancer patients (P <0.05). Conclusion Combined detection of HE4 and CA125 is an ideal method for the detection of ovarian cancer, which provides a basis for early diagnosis and treatment of ovarian cancer.